Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tiantan Biological Products ROE % Adjusted to Book Value Chart
SHSE:600161 vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Beijing Tiantan Biological Products's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tiantan Biological Products ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Tiantan Biological Products's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Beijing Tiantan Biological Products's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 1.69% mean?
Beijing Tiantan Biological Products (SHSE:600161) has a ROE % Adjusted to Book Value of 1.69% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Beijing Tiantan Biological Products and its competitors.
Is Beijing Tiantan Biological Products' ROE % Adjusted to Book Value too high?
Beijing Tiantan Biological Products' current ROE % Adjusted to Book Value is 1.69%. Overall, Beijing Tiantan Biological Products has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tiantan Biological Products' ROE % Adjusted to Book Value compare to VRTX and REGN?
Beijing Tiantan Biological Products' ROE % Adjusted to Book Value of 1.69% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Beijing Tiantan Biological Products and its competitors. Beijing Tiantan Biological Products's current ROE % Adjusted to Book Value is 1.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tiantan Biological Products stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products (SHSE:600161) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥23.94, compared to a current price of ¥12.56 — trading 47.5% below its estimated fair value. The current ROE % Adjusted to Book Value is 1.69%. Beijing Tiantan Biological Products' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Beijing Tiantan Biological Products (SHSE:600161), the current ROE % Adjusted to Book Value is 1.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tiantan Biological Products (SHSE:600161) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products stock appears to be undervalued.
The current stock price of ¥12.56 is trading 47.5% below its estimated GF Value™ of ¥23.94.
GuruFocus considers Beijing Tiantan Biological Products to be Significantly Undervalued.
Key valuation signals for SHSE:600161:
ROE % Adjusted to Book Value: 1.69%
GF Value™: ¥23.94 vs. price of ¥12.56 (47.5% below fair value)
No single metric tells the full story. See the SHSE:600161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tiantan Biological Products Business Description
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.
75GF Score
Get the complete analysis for SHSE:600161
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600161 has been successfully added to your 
